Carbonic Anhydrase Inhibitors and Carbonation: A Novel Approach to Reduce Soda Consumption

Obesity Clinical Trial

Official title:

Carbonic Anhydrase Inhibitors and Carbonation: A Novel Approach to Reduce Soda Consumption

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

• NCT number: NCT06110078
• Other study ID #: STUDY00003535
• Status: Enrolling by invitation
• Phase: Early Phase 1
• Start date: January 18, 2024
• Est. completion date: May 1, 2024

Study information

• Verified date: May 2024
• Source: University of Arizona
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Acetazolamide is a drug that is approved by the FDA for treating various conditions like epilepsy, altitude sickness, and glaucoma. Acetazolamide works by inhibiting an enzyme called carbonic anhydrase, which is important for many essential processes in our body. For example, carbonic anhydrase is needed to transport carbon dioxide in our blood which is essential for respiration.

One of the interesting effects of acetazolamide is that it reduces the taste of carbonation, making carbonated drinks like soda taste flat and or like soapy water. This effect has been noticed by hikers using the drug for mountain sickness treatment. It's believed that carbonic anhydrase inhibitors decrease the levels of carbonic acid in our mouths, which in turn reduces and changes the perception of carbonation taste.

It was hypothesized that this side effect of acetazolamide could be used to help people cut down on soda consumption. Since soda has been linked to health issues like obesity and type 2 diabetes, reducing its intake could be beneficial. In a case study, a person who took low-dose acetazolamide for six weeks experienced weight loss and found it easier to avoid carbonated drinks.

We are proposing a study to explore the effects of using acetazolamide as an oral rinse to decrease soda intake. The use of acetazolamide as an oral rinse has yet to be tested and is a possible way to decrease the taste of carbonation while also decreasing the side effects of the drug. Our plan is to use different doses of the rinse on participants and monitor their soda consumption and body mass index changes.

In summary, acetazolamide, a drug with various medical uses, could potentially help people reduce soda consumption by altering the taste of carbonation.

Recruitment information / eligibility

• Status: Enrolling by invitation
• Enrollment: 44
• Est. completion date: May 1, 2024
• Est. primary completion date: May 1, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 100 Years

Eligibility

Inclusion Criteria:

1. Age = 18 years.

2. Consumes on average = 7 sodas per week

3. Healthy and without a history of significant neurological, liver, renal, cardiac or pulmonary disease.

4. No allergy to sulfa drugs or aspirin (contained in Alka Seltzer).

5. Ability to provide informed consent.

Exclusion Criteria:

Healthy adults, UA students, UA faculty and staff Exclusion Criteria:

1. Pregnant or lactating women.

2. Prisoners.

3. Refugees.

4. Cognitive impairment.

5. Chronic illness.

6. Allergy to sulfa drugs or aspirin.

Related Conditions & MeSH terms

• Obesity

Intervention

Drug:
• Acetazolamide
Oral rinse with acetazolamide (not taken orally)

Locations

Country	Name	City	State
United States	College of Medicine Phoenix U of Arizona	Phoenix	Arizona

Sponsors (1)

Lead Sponsor	Collaborator
University of Arizona

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Soda intake	Total soda/carbonated beverage intake per week	3 weeks
Secondary	Weight	BMI/weight	3 weeks